Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features

Area of Science:

• Microbiology and Infectious Diseases
• Antimicrobial Resistance
• Public Health

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) infections represent a significant global health challenge.
• Vancomycin is a primary therapeutic agent for MRSA infections.
• Emergence of vancomycin-resistant Staphylococcus aureus (VRSA) strains threatens current treatment paradigms.

Purpose of the Study:

• To review recent advancements in understanding Vancomycin-resistant Staphylococcus aureus (VRSA).
• To highlight the mechanisms of VRSA resistance.
• To summarize the clinical characteristics and treatment options for VRSA infections.

Main Methods:

• Literature review of recent scientific publications on VRSA.
• Analysis of reported VRSA resistance mechanisms, focusing on the vanA gene cluster.
• Compilation of data on VRSA isolate prevalence and clinical case studies.

Main Results:

• VRSA is mediated by the vanA gene cluster, typically acquired from vancomycin-resistant enterococci.
• Since 2002, 52 VRSA strains have been identified globally.
• The review synthesizes current knowledge on VRSA's genetic basis, clinical presentation, and therapeutic approaches.

Conclusions:

• VRSA represents a critical public health threat due to vancomycin resistance.
• Understanding the vanA-mediated resistance mechanism is crucial for developing effective interventions.
• Continued surveillance and research into novel treatments are essential for managing VRSA infections.